- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00186706
Selenium Supplementation in Chronic Obstructive Pulmonary Disease (COPD) Patients
The Effect of Selenium Supplementation on Anti-Oxidant Levels in COPD Patients: A 12-Week, Randomized, Placebo-Controlled Trial
Does an oral selenium supplement increase blood levels of antioxidants in patients with established, smoking-related lung disease?
Members of our study group recently discovered that elevated levels of the anti-oxidant GPx-1 may be protective against heart disease. We are studying whether selenium supplementation will improve GPx-1 levels.
Study Overview
Status
Intervention / Treatment
Detailed Description
Patients with chronic obstructive pulmonary disease (COPD) are at high risk for atherosclerotic heart disease, in part because of their nearly universal exposure to heavy smoking, and in part to other incompletely understood mechanisms which may include inflammation and anti-oxidant status.
Smoking markedly affects both circulating inflammatory markers concentrations, and the anti-oxidant glutathione peroxidase-1 (GPx-1). We hypothesize that smoking-related inflammation and anti-oxidant consumption lead to both cardiovascular (CV) and respiratory disease. In a recent study, we (Blankenberg et al) found that higher levels of GPx-1 were associated with lower rates af future CV events and death. GPx-1 levels were lower among smokers, and the combination of current smoking and GPx-1 levels below the median was strongly (HR=5.6) and significantly associated with future CV events and death.
There is a biological and epidemiological rationale to study selenium supplementation for CV protection. GPx-1 is a selenium-dependent enzyme, and data support the hypothesis that selenium supplementation increases GPx activity in various diseases. Furthermore, epidemiologic studies have discovered an inverse association between selenium content in soil and CV incidence and mortality. We hypothesize that selenium supplementation will elevate intra-erythrocytic GPx-1 levels in COPD patients and, ultimately, retard CV progression.
In this study, we will test the first component of this assertion. In a randomized, placebo-controlled trial, we will determine whether 12 weeks of selenium supplementation increases GPx-1 levels among 120 COPD patients. If successful, this study may lead to future large clinical trials to assess whether selenium, an inexpensive and safe mineral, improves clinical outcomes in cardiovascular and respiratory disease.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Ontario
-
Hamilton, Ontario, Canada, L8N 4A6
- St. Joseph's Healthcare
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Aged 40 years or older (no upper limit).
- Established Respirologist-diagnosed mild or moderate COPD, according to the Canadian Thoracic Society (CTS) Lung Function Guidelines.(33) For a diagnosis of mild COPD, patients must have FEV1 60% to 79% predicted and FEV1 / FVC < 0.7. For a diagnosis of moderate COPD, patients must have FEV1 40% to 59% predicted and FEV1 / FVC < 0.7.
- Current or former smokers with > 20 pack-year smoking history.
- Ability to provide informed consent.
- Women subjects must be post-menopausal.
Exclusion Criteria:
- Current or recent (within 4 weeks) acute exacerbation of chronic bronchitis
- Current daily use of mineral or vitamin + mineral supplements or other natural health products that provide a daily dose of selenium that is greater than 100 µg
- Current daily use of >5000 U of vitamin A, >1000 mg of vitamin C, or >800 U vitamin E
- Known significant co-morbidity such as renal (creatinine > 150 mol/L) or hepatic disease (AST or ALT >3 times normal). Measurement of these will be a requirement of the study. Creatinine and Alanine aminotransferase (ALT) will be measured at the beginning and at the end of the study.
- Known or suspected active cancer other than non-melanoma skin cancer.
- Other concurrent major respiratory diagnosis other than COPD/asthma.
- Plan to start statin drugs during the 12 weeks of study drug (may enroll if statins started >1 month before current study enrollment or deferred until study completion).
- Consumption of brazil nuts.
- Individuals who have homocystinuria
- On niacin at a daily dose of 500 mg or higher for hyperlipidemia.
- If you have allergies to products that contain dicalcium phosphate, talc sugarloaf, steric acid, or silica.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
To determine whether 12 weeks of selenium supplementation increases GPx-1 levels compared with placebo
|
Secondary Outcome Measures
Outcome Measure |
---|
To determine whether selenium affects respiratory symptoms and function, and measures of inflammatory and infections markers.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Marek J Smieja, MD PhD FRCPC, Associate Professor, Dept. of Pathology & Molecular Medicine, McMaster University; Microbiologist & Infectious Disease Physician, Dept. of Laboratory Medicine
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- R.P. #04-2326
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiovascular Disease
-
University of FloridaUniversity of Alabama at Birmingham; Brown UniversityCompletedCardiovascular Disease | Psychosocial Influence on Cardiovascular DiseaseUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedCardiovascular Disease | Inflammatory DiseaseUnited States
-
Morehouse School of MedicineNot yet recruiting
-
Yonsei UniversityRecruitingCardiovascular DiseaseKorea, Republic of
-
Nanjing Medical UniversityNot yet recruitingCardiovascular Disease
-
National Human Genome Research Institute (NHGRI)Active, not recruiting
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruiting
-
AmgenCompletedCardiovascular DiseaseUnited States, Australia
-
VA Office of Research and DevelopmentEnrolling by invitationCardiovascular DiseaseUnited States
Clinical Trials on Selenium
-
Vanderbilt UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed
-
Quadram Institute BioscienceFood Standards Agency, United KingdomCompleted
-
Peking Union Medical College HospitalUnknownSelenium Deficiency
-
University of ArizonaNational Cancer Institute (NCI)CompletedProstate Cancer
-
Abbott NutritionCompletedPreterm InfantsUnited States
-
University of CalgaryInternational Centre for Diarrhoeal Disease Research, BangladeshCompleted
-
Vanderbilt UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Terminated
-
Peking Union Medical College HospitalUnknown
-
Neny TrianaCompletedAutism Spectrum DisorderIndonesia
-
University of SurreyCompletedUnspecified Adult Solid Tumor, Protocol SpecificUnited Kingdom